Skip to main content

Are you Dr. Parks?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 31 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Thomas Parks, MD is a physiatrist in Addison, Texas. He is currently licensed to practice medicine in Texas, California, and New Mexico.

Education & Training

  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Physical Medicine and Rehabilitation, 1989 - 1992
  • Medical College of Wisconsin Affiliated Hospitals
    Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1988 - 1989
  • Medical College of Wisconsin Affiliated Hospitals
    Medical College of Wisconsin Affiliated HospitalsInternship, Transitional Year, 1987 - 1988
  • Medical College of Wisconsin
    Medical College of WisconsinClass of 1987

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 1995 - 2026
  • TX State Medical License
    TX State Medical License 2013 - 2025
  • NV State Medical License
    NV State Medical License 1996 - 2025
  • CA State Medical License
    CA State Medical License 1999 - 2025
  • CO State Medical License
    CO State Medical License 1995 - 2015
  • NM State Medical License
    NM State Medical License 1996 - 2000
  • WI State Medical License
    WI State Medical License 1988 - 1999
  • American Board of Physical Medicine and Rehabilitation Physical Medicine & Rehabilitation
  • Join now to see all

Press Mentions

  • City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
    City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic ApplicationsJuly 14th, 2021
  • Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma
    Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell CarcinomaJune 7th, 2021

Professional Memberships